Downregulation of erythroid differentiation regulator 1 as a novel marker of skin tumors

Lee, Young Bok; Kim, Hee Jung; Jung, Hwa Young; Park, Yong Gyu; Kim, Si Yong; Cho, Baik Kee; Cho, Daeho; Park, Hyun Jeong

doi:10.1111/ijd.12057

Cited by 9 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, we found that Erdr1 is expressed in human epidermis, sebaceous glands, eccrine glands, vessels, and nerves [23]. However, the expression of Erdr1 in a healthy hair’s follicular structure has not been yet reported.…”

Section: Discussionmentioning

confidence: 99%

Erythroid Differentiation Regulator 1 as a Novel Biomarker for Hair Loss Disorders

Woo

Hwang

Jeong

et al. 2017

IJMS

View full text Add to dashboard Cite

Erythroid differentiation regulator 1 (Erdr1) is known to be involved in the inflammatory process via regulating the immune system in many cutaneous disorders, such as psoriasis and rosacea. However, the role of Erdr1 in various hair loss disorders remains unclear. The aim of this study was to investigate the putative role of Erdr1 in alopecias. Skin samples from 21 patients with hair loss disorders and five control subjects were retrieved, in order to assess their expression levels of Erdr1. Results revealed that expression of Erdr1 was significantly downregulated in the epidermis and hair follicles of patients with hair loss disorders, when compared to that in the control group. In particular, the expression of Erdr1 was significantly decreased in patients with alopecia areata. We propose that Erdr1 downregulation might be involved in the pathogenesis of hair loss, and could be considered as a novel biomarker for hair loss disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Erythroid Differentiation Regulator 1 as a Novel Biomarker for Hair Loss Disorders

Woo

Hwang

Jeong

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…The erythroid differentiation regulator 1 (Erdr1), which is highly expressed and acts as a survival factor in various cells, was first discovered in murine and human erythroleukaemia cell lines that exhibited hemoglobin synthesis-inducing activity. Erdr1 is usually expressed in normal skin epithelium [ 121 ]; however, we recently demonstrated that epidermal Erdr1 expression was decreased in patients with rosacea compared to controls, whereas IL-18 was upregulated [ 102 ]. Consistent with this inverse correlation, we also observed that the Erdr1 was negatively regulated by IL-18 in rosacea [ 102 ].…”

Section: Abnormalities In Immune Systemmentioning

confidence: 99%

Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition

Woo

Lim

Cho

et al. 2016

IJMS

138

155

View full text Add to dashboard Cite

Rosacea is a chronic cutaneous inflammatory disease that affects the facial skin. Clinically, rosacea can be categorized into papulopustular, erythematotelangiectatic, ocular, and phymatous rosacea. However, the phenotypic presentations of rosacea are more heterogeneous. Although the pathophysiology of rosacea remains to be elucidated, immunologic alterations and neurovascular dysregulation are thought to have important roles in initiating and strengthening the clinical manifestations of rosacea. In this article, we present the possible molecular mechanisms of rosacea based on recent laboratory and clinical studies. We describe the genetic predisposition for rosacea along with its associated diseases, triggering factors, and suggested management options in detail based on the underlying molecular biology. Understanding the molecular pathomechanisms of rosacea will likely aid toward better comprehending its complex pathogenesis.

show abstract

“…The average intensity of the ERDR1 expression was significantly upregulated after PDT compared with the levels before PDT, as analyzed by an unpaired t-test (p = 0.03; Figure 1b). This change implies that the ERDR1 expression after PDT somehow recovered to levels similar to those that are present normally, because the ERDR1 expression is decreased in various skin diseases that are characterized by uncontrolled proliferation, such as AK, psoriasis, and cancer [16][17][18]. ERDR1 protein is highly expressed in keratinocytes and melanocytes, however, its expression is significantly decreased in keratinocytes from patients with psoriasis and in melanocytes from patients with malignant melanoma [16,18].…”

Section: Erdr1 and Photodynamic Therapymentioning

confidence: 98%

“…Dormer et al reported that ERDR1 is a highly conserved protein that is expressed in normal human and mouse tissues [2]. Recent studies also show that the ERDR1 protein is highly expressed in normal skin tissues, and that its expression is significantly decreased in various skin diseases that are characterized by uncontrolled proliferation [16][17][18]. Specifically, the ERDR1 protein is highly expressed in keratinocytes and melanocytes, however, its expression is significantly decreased in the keratinocytes of patients with psoriasis and in the melanocytes of patients with malignant melanoma [16,18].…”

Section: Erdr1 Expression and Apoptosis Controlmentioning

confidence: 99%

“…Specifically, the ERDR1 protein is highly expressed in keratinocytes and melanocytes, however, its expression is significantly decreased in the keratinocytes of patients with psoriasis and in the melanocytes of patients with malignant melanoma [16,18]. Additionally, ERDR1 protein levels are negatively correlated with skin malignancies, and its expression level in psoriasis and AK is often reduced, relative to normal controls, but is higher than that in skin tumors such as squamous cell carcinoma (SCC) or melanoma [17]. Overall, ERDR1 expression is responsible for the condition of the skin, i.e., normal levels of expression result in the maintenance of homeostasis and decreased levels lead to uncontrolled proliferation.…”

Section: Erdr1 Expression and Apoptosis Controlmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Erythroid Differentiation Regulator 1 (ERDR1) in the Control of Proliferation and Photodynamic Therapy (PDT) Response

Park¹,

Kim

Park

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Erythroid differentiation regulator 1 (ERDR1) was newly identified as a secreted protein that plays an essential role in maintaining cell growth homeostasis. ERDR1 enhances apoptosis at high cell densities, leading to the inhibition of cell survival. Exogenous ERDR1 treatment decreases cancer cell proliferation and tumor growth as a result of increased apoptosis via the regulation of apoptosis-related gene expression. Moreover, ERDR1 plays a pivotal role in skin diseases; ERDR1 expression in actinic keratosis (AK) is negatively correlated with the increase in apoptosis. Because of its high specificity and efficiency, photodynamic therapy (PDT) is a common therapy for patients with various skin diseases, including cancer. Many studies indicate that apoptosis is mainly induced by PDT treatment. As an apoptosis inducer, the recovery of the ERDR1 expression after PDT is correlated with good therapeutic outcomes. Here, we review recent findings that highlight the function of ERDR1 in the control of apoptosis. Thus, ERDR1 may have a role in the apoptosis regulation of target cells in the lesions, as the recovery of its expression after PDT is correlated with good therapeutic outcomes.

show abstract

Downregulation of erythroid differentiation regulator 1 as a novel marker of skin tumors

Cited by 9 publications

References 21 publications

Erythroid Differentiation Regulator 1 as a Novel Biomarker for Hair Loss Disorders

Erythroid Differentiation Regulator 1 as a Novel Biomarker for Hair Loss Disorders

Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition

The Role of Erythroid Differentiation Regulator 1 (ERDR1) in the Control of Proliferation and Photodynamic Therapy (PDT) Response

Contact Info

Product

Resources

About